Insider · CIK 0001799365

Bigora Sian

Reports to the SEC for 1 company · VERO BEACH, FL

sec.gov

Transactions

Companies

Filings

CIK

0001799365

Forms 4 and 5

Insider transactions

40 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-04-30	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Chief Development Officer	PPurchase	+1,971 sh	$2.71	+$5,341.41	7,481
2026-04-30	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Chief Development Officer	PPurchase	+1,986 sh	$2.69	+$5,342.34	7,496
2026-04-15	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Chief Development Officer	PPurchase	+1,799 sh	$2.97	+$5,343.03	5,510
2026-03-31	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Chief Development Officer	PPurchase	+2,107 sh	$2.54	+$5,341.245	3,711
2026-01-01	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−249 sh	—	—	0
2026-01-01	PCSAProcessa Pharmaceuticals, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+249 sh	—	—	1,604
2025-10-01	PCSAProcessa Pharmaceuticals, Inc. · Stock Options (Right to Buy)A Award	Chief Development Officer	AAward	+288K sh	—	—	288,000
2025-10-01	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+96K sh	—	—	96,000
2025-07-24	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+1.66M sh	—	—	1,672,087
2025-04-01	PCSAProcessa Pharmaceuticals, Inc.F Tax Payment	Chief Development Officer	FTax Payment	−3,311 sh	$0.41	−$1,364.132	33,626
2025-04-01	PCSAProcessa Pharmaceuticals, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+15.1K sh	—	—	36,937
2024-07-10	PCSAProcessa Pharmaceuticals, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+644 sh	—	—	22,103
2024-07-10	PCSAProcessa Pharmaceuticals, Inc.F Tax Payment	Chief Development Officer	FTax Payment	−225 sh	$1.71	−$384.75	21,878
2024-06-28	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+404 sh	—	—	27,961
2024-06-28	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+404 sh	—	—	27,557
2024-06-28	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+2,425 sh	—	—	27,153
2024-06-28	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+3,233 sh	—	—	24,728
2024-04-05	PCSAProcessa Pharmaceuticals, Inc.F Tax Payment	Chief Development Officer	FTax Payment	−368 sh	$2.79	−$1,026.72	21,459
2024-04-05	PCSAProcessa Pharmaceuticals, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+1,675 sh	—	—	21,827
2024-01-01	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−1,675 sh	—	—	22,139
2024-01-01	PCSAProcessa Pharmaceuticals, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+1,675 sh	—	—	21,826
2024-01-01	PCSAProcessa Pharmaceuticals, Inc.F Tax Payment	Chief Development Officer	FTax Payment	−368 sh	$2.79	−$1,026.72	21,458
2023-01-01	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+75.9K sh	—	—	431,985
2023-01-01	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+48.5K sh	—	—	480,475
2022-12-31	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+13.9K sh	—	—	356,073
2022-09-30	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+13.9K sh	—	—	342,227
2022-08-05	PCSAProcessa Pharmaceuticals, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+7,601 sh	—	—	403,019
2022-06-30	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+25.6K sh	—	—	328,377
2022-04-01	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+248K sh	—	—	302,766
2022-03-31	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+10.7K sh	—	—	37,781
2021-12-31	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+6,722 sh	—	—	22,780
2021-12-31	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+6,722 sh	—	—	6,722
2021-11-01	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+4,286 sh	—	—	27,066
2021-09-30	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+6,024 sh	—	—	16,058
2021-09-30	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+6,024 sh	—	—	6,024
2021-08-05	PCSAProcessa Pharmaceuticals, Inc.A Award	Chief Development Officer	AAward	+7,601 sh	—	—	395,418
2021-07-08	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+12.9K sh	—	—	12,858
2021-07-08	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+1,907 sh	—	—	10,034
2021-07-08	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+8,572 sh	—	—	8,572
2021-06-08	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+8,127 sh	—	—	8,127

Recent filings

Accepted (ET)
May 194/A
Bigora Sian0000897069-26-001154
SEC(opens sec.gov)
May 14
Bigora Sian0000897069-26-001000
SEC(opens sec.gov)
Apr 174
Bigora Sian0000897069-26-000904
SEC(opens sec.gov)
Apr 14
Bigora Sian0000897069-26-000743
SEC(opens sec.gov)
Feb 44
Bigora Sian0000897069-26-000218
SEC(opens sec.gov)
Oct 34
Bigora Sian0000897069-25-001549
SEC(opens sec.gov)
Jul 284
Bigora Sian0000897069-25-001219
SEC(opens sec.gov)
Apr 114
Bigora Sian0000897069-25-000789
SEC(opens sec.gov)
Aug 24
Bigora Sian0000897069-24-001615
SEC(opens sec.gov)
Apr 124
Bigora Sian0000897069-24-000919
SEC(opens sec.gov)

Companies

Processa Pharmaceuticals, Inc.Chief Development OfficerPCSA

Address

C/O PROCESSA PHARMACEUTICALS, INC. 601 21ST STREET SUITE 300

VERO BEACH, FL, 32960